<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435003</url>
  </required_header>
  <id_info>
    <org_study_id>1074296-3</org_study_id>
    <nct_id>NCT03435003</nct_id>
  </id_info>
  <brief_title>Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy</brief_title>
  <official_title>Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bariatric surgery remains the most effective therapy for obesity. Postoperative nausea and
      vomiting (PONV) are commonly reported following bariatric surgery. The proposed study focuses
      on the most common bariatric procedure performed, laparoscopic sleeve gastrectomy (LSG), and
      aims to assess the effect of a post-operative nausea and vomiting-specific intervention. The
      investigators hypothesize that the intervention group will experience a reduction of
      nausea-related prolonged hospital stay and significantly improve patient-reported quality of
      recovery from surgery and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test this hypothesis, participants undergoing sleeve gastrectomy will be randomized to two
      groups: control vs Nausea specific-intervention group. All subjects will be assessed with a
      nausea specific questionnaire at 1, 4, 12, 24 hours and 3 weeks after surgery. Patient
      satisfaction with recovery will be assessed using specialized questionnaires at baseline, 24
      hrs. and 3 weeks following surgery. Serial assessments of nausea, vomiting, quality of life
      and quality of recovery, will allow the investigators to identify an effect on incidence and
      severity of Post-operative Nausea and Vomiting. Importantly, the investigators will evaluate
      for an impact in patient-reported measures of quality of life.

      The total sample size is 82. This study will provide valuable insight on the epidemiology of
      post-operative nausea and vomiting after hospital discharge following Sleeve gastrectomy,
      which is currently poorly characterized. By allowing the investigators to assess the overall
      incidence of nausea and vomiting at different time points, this study will afford the
      opportunity to identify a time period of high incidence and further adjust our prevention
      efforts accordingly in future studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Anticipated">August 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of PONV-related delay of hospital discharge</measure>
    <time_frame>Postoperative day 1</time_frame>
    <description>The primary outcome would be incidence of PONV-related delay of hospital discharge following laparoscopic gastrectomy. Based on the current clinical pathway, patients are expected to be discharged on postoperative day 1 (day after surgery). A delay in discharge due to PONV will be the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of PONV measured using a visual analogue scale</measure>
    <time_frame>Baseline, 1 hour, 4 hours, 12 hours, 24 hours and 3 weeks</time_frame>
    <description>The severity of PONV will be measured using a visual analogue scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of PONV measured using the Rhodes Index</measure>
    <time_frame>Baseline, 1 hour, 4 hours, 12 hours, 24 hours and 3 weeks</time_frame>
    <description>The severity of PONV will be measured using the Rhodes Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery measured using the QoR-15 survey</measure>
    <time_frame>24 hours and 3 weeks</time_frame>
    <description>The quality of recovery from laparoscopic sleeve gastrectomy will be measured using the QoR-15 survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI specific quality of life using the GIQLI survey</measure>
    <time_frame>Baseline, 24 hours and 3 weeks</time_frame>
    <description>Patients will be assessed for any perioperative changed in their quality of life using the GIQLI survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall quality of life using the EQ-5D instrument</measure>
    <time_frame>Baseline, 24 hours and 3 weeks</time_frame>
    <description>Patients will be assessed for any perioperative changed in their quality of life using the EQ-5D instrument.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Post-operative Nausea and Vomiting</condition>
  <condition>Laparoscopic Sleeve Gastrectomy</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A) Pre-operatively: aprepitant 80 mg oral capsule and scopolamine transdermal patch.
B) Intra-operatively: total intravenous anesthesia (TIVA) will be maintained with IV infusions of propofol, and dexmedetomidine infusion or intermittent bolus dosing of fentanyl after induction. Sugammadex (2-4 mg/Kg IV) will be used for reversal of neuromuscular blockade in both groups. A single dose of dexamethasone 8 mg IV will be administered after induction, and a single dose of ondansetron 4 mg IV will be administered approximately 20 minutes prior to the end of operation.
C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A) Pre-operatively: No intervention
B) Intra-operatively: inhalation anesthetics (sevoflurane or desflurane) and intermittent opioid boluses will be used for maintenance of anesthesia, as standard practice in the institution of the investigators and across the country. PONV prevention measures in the control group will be limited to dexamethasone 8 mg and ondansetron 4 mg.
C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant 80Mg Oral Capsule</intervention_name>
    <description>aprepitant 80 mg orally one hour prior to scheduled surgery</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>scopolamine transdermal</intervention_name>
    <description>scopolamine transdermal patch one hour prior to scheduled surgery</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <other_name>Transderm Scop</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total intravenous anesthesia</intervention_name>
    <description>Maintenance of anesthesia without the use of inhaled anesthetics.</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 8 mg intraoperatively</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reglan</intervention_name>
    <description>Postoperatively scheduled Reglan</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Metoclopramide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Postoperatively scheduled ondansetron</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compazine</intervention_name>
    <description>Postoperatively as needed compazine for breakthrough PONV</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Compro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Reversal with sugammadex</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Bridion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Intravenous anesthesuia will be maintained through IV propofol</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>maintainance of anesthesia in the intervention arm</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>intermittent bolus dosing of fentanyl will be used after induction for anesthesia maintenance</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>inhalational anesthesia</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Ultane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <description>inhalational anesthesia</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (18 years and older) undergoing LSG

        Exclusion Criteria:

          -  Allergy to medications delineated in the protocol (muscle blockade, anesthetics,
             reversal agents)

          -  Inability to provide informed consent

          -  History of chronic nausea and emesis requiring medication

          -  Poorly controlled diabetes (HgA1c&gt;9 mg/dl),

          -  History of previous bariatric or gastro-esophageal surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Konstantinos Spaniolas, MD</last_name>
    <phone>631-444-7298</phone>
    <email>konstantinos.spaniolas@stonybrookmedicine.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shabana Humayon</last_name>
    <phone>6316380292</phone>
    <email>shabana.humayon@stonybrookmedicine.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8191</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Spaniolas, MD</last_name>
      <phone>631-444-7298</phone>
      <email>konstantinos.spaniolas@stonybrookmedicine.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shabana Humayon</last_name>
      <phone>6316380292</phone>
      <phone_ext>Humayon</phone_ext>
      <email>shabana.humayon@stonybrookmedicine.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>Konstantinos Spaniolas</investigator_full_name>
    <investigator_title>Associate Professor of Surgery, School of Medicine Bariatric, Foregut and Advanced GI Surgery</investigator_title>
  </responsible_party>
  <keyword>Bariatric Procedure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Prochlorperazine</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

